These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19667155)

  • 1. A phase II trial of calcitriol and naproxen in recurrent prostate cancer.
    Srinivas S; Feldman D
    Anticancer Res; 2009 Sep; 29(9):3605-10. PubMed ID: 19667155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma.
    Beer TM; Lemmon D; Lowe BA; Henner WD
    Cancer; 2003 Mar; 97(5):1217-24. PubMed ID: 12599228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.
    Lin AM; Rini BI; Weinberg V; Fong K; Ryan CJ; Rosenberg JE; Fong L; Small EJ
    BJU Int; 2006 Oct; 98(4):763-9. PubMed ID: 16796694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer.
    Trump DL; Potter DM; Muindi J; Brufsky A; Johnson CS
    Cancer; 2006 May; 106(10):2136-42. PubMed ID: 16598750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
    Morris MJ; Smaletz O; Solit D; Kelly WK; Slovin S; Flombaum C; Curley T; Delacruz A; Schwartz L; Fleisher M; Zhu A; Diani M; Fallon M; Scher HI
    Cancer; 2004 May; 100(9):1868-75. PubMed ID: 15112267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer.
    Siemens DR; Heaton JP; Adams MA; Kawakami J; Graham CH
    Urology; 2009 Oct; 74(4):878-83. PubMed ID: 19476985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
    Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
    BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
    Daniels S; Robbins J; West CR; Nemeth MA
    Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcitriol in the treatment of prostate cancer.
    Beer TM; Myrthue A
    Anticancer Res; 2006; 26(4A):2647-51. PubMed ID: 16886675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The promiscuous receptor.
    Newsom-Davis TE; Kenny LM; Ngan S; King J; Waxman J
    BJU Int; 2009 Nov; 104(9):1204-7. PubMed ID: 19426197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis.
    White WB; Schnitzer TJ; Fleming R; Duquesroix B; Beekman M
    Am J Cardiol; 2009 Sep; 104(6):840-5. PubMed ID: 19733721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
    Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
    Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin.
    Schiff M; Hochberg MC; Oldenhof J; Brune K
    Curr Med Res Opin; 2009 Oct; 25(10):2471-7. PubMed ID: 19678751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy].
    Ehara H; Katoh S; Nakane K; Katoh T; Takada T; Kojima K; Kamei S; Hagiwara N; Yuhara K; Takahashi Y; Fujimoto Y; Fujihiro S; Kanimoto Y; Deguchi T
    Hinyokika Kiyo; 2009 Apr; 55(4):199-203. PubMed ID: 19462824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current applications for prostate-specific antigen doubling time.
    Ramírez ML; Nelson EC; Devere White RW; Lara PN; Evans CP
    Eur Urol; 2008 Aug; 54(2):291-300. PubMed ID: 18439749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer.
    Shaw G; Oliver RT
    Surg Oncol; 2009 Sep; 18(3):275-82. PubMed ID: 19269165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hypocalcemia caused by hypoparathyroidism or pseudohypoparathyroidism with domestic-made calcitriol: a prospective and self-controlled clinical trial.
    Wang O; Xing XP; Meng XW; Xia WB; Li M; Jiang Y; Hu YY; Liu HC
    Chin Med J (Engl); 2009 Feb; 122(3):279-83. PubMed ID: 19236804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic non-bacterial osteomyelitis in children.
    Girschick HJ; Raab P; Surbaum S; Trusen A; Kirschner S; Schneider P; Papadopoulos T; Müller-Hermelink HK; Lipsky PE
    Ann Rheum Dis; 2005 Feb; 64(2):279-85. PubMed ID: 15647436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Secondary endocrine therapy with oral estrogen for relapsed prostate cancer].
    Onita T; Igawa T; Hisamatsu H; Sakai H; Kanetake H
    Hinyokika Kiyo; 2009 Oct; 55(10):595-8. PubMed ID: 19926941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.